Antimicrobial Agents and Chemotherapy · 2020 · 18 citations · 29 references
PharmacyPharmacokineticsPharmacologyCritical Care PharmacologyCritical Care PharmacotherapyPopulation PharmacokineticsCritical Care Therapeutic Drug MonitoringPharmacokinetics In Critical IllnessContinuous Negative Pressure TherapyContinuous Renal Replacement Therapy PharmacokineticsCritical Care DosingCritical Care Drug DosingCritical Illness Empiric TherapyCritically Ill Patient DosingDrug Dosing During Continuous Renal Replacement TherapyPopulation Pharmacokinetic Monitoring
The aim was to assess the appropriateness of recommended regimens for empirical MIC coverage in critically ill patients with open-abdomen and negative-pressure therapy (OA/NPT). Over a 5-year period, every critically ill patient who received amikacin and who underwent therapeutic drug monitoring (TDM) while being treated by OA/NPT was retrospectively included. A population pharmacokinetic (PK) modeling was performed considering the effect of 10 covariates (age, sex, total body weight [TBW], adapted body weight [ABW], body surface area [BSA], modified sepsis-related organ failure assessment [SOFA] score, vasopressor use, creatinine clearance [CL CR ], fluid balance, and amount of fluids collected by the NPT over the sampling day) in patients who underwent continuous renal replacement therapy (CRRT) or did not receive CRRT.
29